Skip to Content

'
Sapna Patel, M.D.

Present Title & Affiliation

Primary Appointment

Assistant Professor, Department of Melanoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd
Unit Number: 430
Houston, TX 77030
Room Number: FC11.3016
Phone: 713-792-2921
Fax: 713-745-1046

Education & Training

Degree-Granting Education

2005 The University of Texas Medical Branch, Galveston, TX, MD, Medicine
2000 The University of Texas at Austin, Austin, TX, BA, Microbiology

Postgraduate Training

7/2008-1/2011 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
7/2006-6/2008 Clinical Residency, Internal Medicine, The University of Colorado at Denver and Health Sciences Center, Denver, CO
6/2005-6/2006 Clinical Internship, Internal Medicine, The University of Colorado at Denver and Health Science Center, Denver, CO

Board Certifications

8/2008 American Board of Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Fellowship Director of Moonlighting, Department of Hematology/Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 4/2010-1/2011

Other Appointments/Responsibilities

Clinical Specialist, University of Texas M. D. Anderson Cancer Center, Houston, TX, 11/2008-1/2011

Honors and Awards

2010 Allison and Brian Grove Endowed Fellowship for Breast Medical Oncology
2010 ASCO Cancer Foundation Merit Award, ASCO
2010 ASCO Cancer Foundation Merit Award, ASCO-NCI-EORTC
2009 Ocular Melanoma Foundation Young Investigator Award
2006-2007 Finalist, Humanism andExcellence in Teaching, The University of Colorado at Denver and Health Sciences Center School of Medicine
2006 2nd Place, Rocky Mountain Hospitalist Symposium Abstract Competition
2006 2nd Place, Biosymposia Signaling Transduction Modulators in Cancer Therapy Symposium
1999 College of Natural Sciences Honor List, The University of Texas at Austin
1999 College Scholar, The University of Texas at Austin

Professional Memberships

American Association of Physicians of Indian Origin Medical Students, Residents and Fellows Section
Member, 8/2008-present
American Board of Internal Medicine
Diplomat, 8/2008-12/2018
American College of Physicians
Associate Member, 2006-2007
American Medical Association
Member, 2001-2008
American Society of Clinical Oncology
Associate Member, 7/2009-present
Golden Key International Honor Society
Member, 1999-2000
Network of Indian Professionals
Member, 8/2008-present
Sigma XI Scientific Research Society
Member, 1998-2007
Texas Medical Association
Member, 2008-2009
Texas Medical Association
Member, 2001-2005

Selected Publications

Peer-Reviewed Original Research Articles
1. Patel SP, Kim KB. Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. Expert Opin Investig Drugs 21(4):531-9, 4/2012. e-Pub 3/2012. PMID: 22394161.
2. Patel SP, Kim KB, Papadopoulos NE, Hwu WJ, Hwu P, Prieto VG, Bar-Eli M, Zigler M, Dobroff A, Bronstein Y, Bassett RL, Vardeleon AG, Bedikian AY. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res 21(4):357-63, 8/2011. PMCID: PMC3132394.
3. Kolandjian NA, Patel SP, Papadopoulos NE, Bedikian AY. The left ventricle as the first site of uveal melanoma metastasis 13 years after treatment of the primary tumor. Melanoma Res 21(2):160-3, 4/2011. PMID: 21346640.

Invited Articles
1. Patel SP, Woodman SE. Profile of ipilimumab and its role in the treatment of metastatic melanoma. Drug Des Devel Ther 2011(5):489-495, 2011. e-Pub 12/16/2011. PMCID: PMC3257959.
2. Trinh VA, Patel SP, Hwu WJ. The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 8(4):493-9, 7/2009. PMID: 19435405.
Other Articles
1. Patel SP. "Peginterferon alfa-2b (sylatron) for Melanoma". The Medical Letter on Drugs and Theraputics(1373), 2011.

Abstracts
1. Patel SP, Bedikian AY, Hwu WJ, Kim KB, Homsi J, Davies MA, Woodman SE, Radvanyi L, Woodard K, Mahoney SL, Hwu P. Ipilimumab plus temozolomide in metastatic melanoma, 6/2011.
2. Patel SP, Lazar AJ, Mahoney S, Vaughn C, Gonzalez N, Papadopoulous NE, Liu P, Infante JR, LoRusso PM, Kim KB. Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutation in patients with metastatic melanoma, 10/2010.
3. Patel SP, Lazar AJ, Mahoney S, Vaughn C, Gonzalez N, Papadopoulous N, Liu P, Infante JR, LoRusso PM, Kim KB. Clinical responses to AZD6244 (ARRY-142886)-based combination therapy stratified by gene mutation in patients with metastatic melanoma, 6/2010.
4. Patel S, Bedikian A, Papadopoulos N, Hwu P, Vardeleon A, Prieto V, Bar-Eli M, Bronstein Y, Bassett R, Kim K. A Phase II Study of Gefitnib (IRESSA) in Patients with Metastatic Melanoma, 6/2009.

Book Chapters
1. Joseph RW, Kim K, Patel SP. Ch. 27: Role of Chemotherapy, biochemotherapy, and targeted systemic therapies in the treatment of melanoma. In: Cutaneous Malignancy of the Head and Neck. Plural Publishing, 2011.
2. Patel SP, Buzdar AU. Ch.24: Early and locally advanced breast cancer. In: M. D. Anderson Manual of Medical Oncology 2nd ed. McGraw-Hill, 2011.

Last updated: 1/3/2012